Corzo L, Fernández-Novoa L, Carrera I, Martínez O, Rodríguez S, Alejo R and Cacabelos R. 2020. Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals. Nutrients 12(3):747.

Lombardi VRM, Carrera I, Corzo L, Cacabelos R. 2019. Role of bioactive lipofishins in prevention of inflammation and colon cancer. Seminars in Cancer Biology, 56: 175-184.

Cacabelos R, Lombardi VRM, Fernández-Novoa l, Carrera I, Cacabelos P, Corzo L, Carril JC, Teijido O. 2018. Chapter 6 – Basic and Clinical Studies With Marine LipoFishins and Vegetal Favalins in Neurodegeneration and Age-Related Disorders. 59:195-225.

Lombardi VRM, Carrera I, Cacabelos R. 2018. In vitro and in vivo cytotoxic effect of AntiGan against tumor cells. Exp Ther Med., 15(3):2547-2556.

Cacabelos R, Meyyazhagan A, Carril JC, Cacabelos P, Teijido O. 2018. Pharmacogenetics of Vascular Risk Factors in Alzheimer’s Disease. J. Pers. Med., 8(1), 3.

Lombardi VRM, Corzo L, Carrera I and Cacabelos R. 2018. The search for biomarine derived compounds with immunomodulatory activity. J Explor Res Pharmacol.3(1):30-41.

Corzo L, Rodríguez S, Alejo R, Fernandez-Novoa L, Aliev G, Cacabelos R. 2017. E-MHK-0103 (Mineraxin™): A Novel Nutraceutical with Biological Properties in Menopausal Conditions. Curr Drug Metab., 18(1):39-49.

Cacabelos R, Carril JC, Teijido O. 2017. Chapter 5. Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development. Anti-aging Drugs: From Basic Research to Clinical Practice, 75-141.

Cacabelos R. 2017. ProteoLipins and LipoFishins: Novel nutraceuticals and their effects. Open Access Government. Health & Social Care News, January 20.

Cacabelos R. 2016. Novel Biotechnological Products from Natural Sources: Nutri/Pharmacogenomic Component. J Nutr Food Sci, 6:6.

Kwak C-H, Lee S-H, Lee S-K, Ha S-H, Suh S-J et al. 2015. Induction of Apoptosis and Antitumor Activity of Eel Skin Mucus, Containing Lactose-Binding Molecules, on Human Leukemic K562 Cells. Drugs, 13(6), 3936-3949.

Cacabelos R, Cacabelos P, Torrellas C, Tellado I, Carril JC. 2014. Pharmacogenomics of Alzheimer’s disease: Novel Therapeutic Strategies for Drug Development. In: Yan Q. (eds) Pharmacogenomics in Drug Discovery and Development. Methods in Molecular Biology (Methods and Protocols), vol 1175. Humana Press, New York, NY.

Watanabe Y, Naganuma T, Ogawa T, Muramoto K. 2013. Lectins of Marine Origin and Their Clinical Applications. In: Fang E., Ng T. (eds) Antitumor Potential and other Emerging Medicinal Properties of Natural Compounds. Springer, Dordrecht. 3, 33-54.

Nakamura O, Watanabe M, Ogawa T, Muramoto K, Ogawa K, Tsutsui S, Kamiyaa H. 2012. Galectins in the abdominal cavity of the conger eel Conger myriaster participate in the cellular encapsulation of parasitic nematodes by host cells. Fish & Shellfish Immunology, 33: 780-787.

Cacabelos R, Fernández-Novoa L, Martínez-Bouza R, McKay A, Carril JC, Lombardi VRM, Corzo L, Carrera I, Tellado I, Nebril L, Alcaraz M, Rodríguez S, et al. 2010. Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. Pharmaceuticals, 3: 3040-3100.

Cacabelos R. 2008. Application of nutrigenomics to Alzheimer’s disease. Agro Food Industry Hi-Tech. 19.

Lombardi VRM, Pereira J, Etcheverría I, Fernández-Novoa L, Seoane S and Cacabelos R. 2006. Improvement of immune function by means of Conger conger extract in an in vivo rat model of cold stress. Food and Agricultural Immunology, 17(1-4): 115-127.

Lombardi VRM, Fernandez-Novoa L, Etcheverria I, Seoane S, Cacabelos R. 2005. Effects of fish-derived lipoprotein extracts on activation markers, Fas expression and apoptosis in peripheral blood lymphocytes. International Immunopharmacology, 5: 253-262.

Lombardi VRM, Fernandez-Novoa L, Etcheverria I, Seoane S, Cacabelos R. 2005. Studies on immunological, biochemical, hematological and growth regulation by Scomber scombrus fish protein extract supplementation in young pigs. Animal Science Journal, 76: 159-170.

Cacabelos R. 2005. Role of Nutrition in the Prevention of Alzheimer´s Disease. Aging Health, 1(3): 359-362.

Cacabelos R. 2005. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer’s disease. Future Medicine. Aging Health, 1(2):303-348.

Cacabelos R, Vallejo AI, Lombardi VRM, Fernández-Novoa L and Pichel V. 2004. E-SAR-94010®: a pleiotropic lipoprotein compound with powerful anti-atheromatous and lipid lowering effects. CNS Drug Reviews, vol. 10 (2).

Lombardi VRM, Fernandez-Novoa L, Corzo D, Zas R, Cacabelos R. 2002. Enhancement in Immune Function and Growth Using E-JUR-94013®. Methods Find Exp Pharmacol, 24 (9): 573:578.

Lombardi VRM, Cagiao A, Fernández-Novoa L, Álvarez XA, Corzo L, Zas R, Sampedro C, Cacabelos R. 2001. Short term food supplementation effects of a fish derived extract on the immunological status of pregnant rats and their sucking pups. Nutrition Research, 21(11):1425-1434.

Lombardi V.R.M., Cacabelos R. 1999. E-SAR-94010: A marine fish extract obtained by advanced biotechnological methods. Drugs Fut, 24(2): 167.

Cacabelos R, Carrera I, Martínez O, Naidoo V, Cacabelos N, Aliev G, Carril JC. 2021. Influence of dopamine, noradrenaline, and serotonin transporters on the pharmacogenetics of Atremorine in Parkinson’s disease. Drug Dev Res, 1–12.

Corzo L, Fernández-Novoa L, Carrera I, Martínez O, Rodríguez S, Alejo R and Cacabelos R. 2020. Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals. Nutrients, 12(3):747.

Martínez-Iglesias O, Naidoo V, Carril JC, Carrera I, Corzo L, Rodríguez S, Alejo R, Cacabelos N, Cacabelos R. 2020. AtreMorine Treatment Regulates DNA Methylation in Neurodegenerative Disorders: Epigenetic and Pharmacogenetic Studies. Current Pharmacogenomics and Personalized Medicine, 17, 159-171.

Cacabelos R. 2020. Pharmacogenomics of Alzheimer’s and Parkinson’s diseases. Neurosci Lett, 726: 133807.

Cacabelos R, Carrera I, Alejo R, Fernández-Novoa L, Cacabelos P, Corzo L, Rodríguez S, Alcaraz M, Tellado I, Cacabelos N, Pego R, Carril JC. 2019. Pharmacogenetics of Atremorine-Induced Neuroprotection and Dopamine Response in Parkinson’s Disease. Planta Med., 85(17):1351-1362.

Qazi IH, Angel C, Yang H, Zoidis E, Pan B, Wu Z, Ming Z, Zeng CJ, Meng Q, Han H, Zhou G. 2019. Role of Selenium and Selenoproteins in Male Reproductive Function: A Review of Past and Present Evidences. Antioxidants (Basel) 2019, 2;8(8):268.

Teijido O., Cacabelos R. 2018. Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer’s and Parkinson’s Diseases. Int. J. Mol. Sci., 19, 3199.

Carrera I, Fernandez-Novoa L, Sampedro C, Tarasov VV, Aliev G, Cacabelos R. 2018. Dopaminergic Neuroprotection with AtreMorine in Parkinson´s Disease. Current Medicinal Chemistry, 25: 5372. 

Cacabelos R, Lombardi VRM, Fernández-Novoa l, Carrera I, Cacabelos P, Corzo L, Carril JC, Teijido O. 2018. Chapter 6 – Basic and Clinical Studies With Marine LipoFishins and Vegetal Favalins in Neurodegeneration and Age-Related Disorders. 59:195-225.

Cacabelos R, Carril JC, Cacabelos P, Fernández-Novoa L, Arun M. 2017. Pharmacogenetics of Neurodegenerative disorders. Internal Medicine Review, 3. 10.18103/imr.v3i6.472.

Cacabelos R. 2017. Parkinson’s Disease: From Pathogenesis to Pharmacogenomics. Int. J. Mol. Sci., 18(3), 551.

Cacabelos R, Carril JC, Teijido O. 2017. Chapter 5. Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development. Anti-aging Drugs: From Basic Research to Clinical Practice, 75-141.

Romero A, Parada E, González‐Lafuente L, Farré‐Alins V, Ramos E, Cacabelos R, Egea J. 2017. Neuroprotective effects of E‐PodoFavalin‐15999 (Atremorine®). CNS Neurosci Ther, 23:450‐452.

Carrera I, Fernandez-Novoa L, Sampedro C, Cacabelos R. 2017. Neuroprotective Effect of AtreMorine in an Experimental Model of Parkinson’s disease. Current Pharmaceutical Design, Vol 23 (18): 2673-2684(12).

Cacabelos R. 2016. Novel Biotechnological Products from Natural Sources: Nutri/Pharmacogenomic Component. J Nutr Food Sci, 6:6.

Cacabelos R, Fernández-Novoa L, Alejo R, Corzo L, Alcaraz M, Nebril L, Cacabelos P, Fraile C, Carrera I and Carril JC. 2016. E-PodoFavalin-15999 (Atremorine®)-Induced Neurotransmitter and Hormonal Response in Parkinson’s disease. J Exp Res Pharm , 1(1):1-12.

Cacabelos R, Fernández-Novoa L, Alejo R, Corzo L, Alcaraz M, Nebril L, Cacabelos P, Fraile C, Carrera I and Carril JC. 2016. E-PodoFavalin-15999 (Atremorine®)-Induced Dopamine Response in Parkinson’s disease: Pharmacogenetics-Related Effects. Gen Med Pharm, 1(1):1‐26.

Shipton MJ, Thachil J. 2015. Vitamin B12 deficiency – A 21st century perspective. Clin Med, 15(2):145-50.

Bailey LB, Stover PJ, McNulty H, Fenech MF, Gregory JF 3rd, et al. 2015. Biomarkers of Nutrition for Development-Folate Review. J Nutr, 145(7):1636S-80S.

Gonzales GF. 2012. Ethnobiology and Ethnopharmacology of Lepidium meyenii (Maca), a Plant from the Peruvian Highlands. Evid Based Complement Alternat Med, 193496.

Lee MS, Shin BC, Yang EJ, Lim HJ, Ernst E. 2011. Maca (Lepidium meyenii) for treatment of menopausal symptoms: A systematic review. Maturitas, 70(3):227-33.

Zenico T, Cicero AF, Valmorri L, Mercuriali M, Bercovich E. 2009. Subjective effects of Lepidium meyenii (Maca) extract on well-being and sexual performances in patients with mild erectile dysfunction: a randomised, double-blind clinical trial. Andrologia, 41(2):95-9.

Abugoch James LE. 2009. Quinoa (Chenopodium quinoa Willd.): composition, chemistry, nutritional, and functional properties. Adv Food Nutr Res, 58:1-31.

Peters R, Burch L, Warner J, Beckett N, Poulter R, Bulpitt C. 2008. Haemoglobin, anaemia, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr, 8, 8:18.

Prasad AS, Mantzoros CS, Beck FW, Hess JW, Brewer GJ. 1996. Zinc status and serum testosterone levels of healthy adults. Nutrition, 12(5):344-348.

Cacabelos R, Álvarez XA, Franco A, Fernández-Novoa L, Caamaño J, Valle-Inclán F. 1992. Therapeutic effects of CDP-choline in Alzheimer’s disease and multi-infarct dementia: psychometric assessment and immune function. Ann Psychiat, 3: 233-245.

 

Cacabelos R, Alvarez XA, Franco-Maside A, Fernández-Novoa L, Caamaño J. 1993. Effect of CDP-choline on cognition and immune function in Alzheimer’s disease and multi-infarct dementia. Ann N Y Acad Sci. 24, 695:321-3. doi: 10.1111/j.1749-6632. 1993.tb23076.x. PMID: 8239305

 

Caamaño J, Gómez MJ, Franco A, Cacabelos R. 1994. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer’s disease. Methods Find Exp Clin Pharmacol, 16(3): 211-8. PMID: 7913981

 

Fernández-Novoa L, Alvarez XA, Franco-Maside A, Caamaño J, Cacabelos R. 1994. CDP-choline-induced blood histamine changes in Alzheimer’s disease. Methods Find Exp Clin Pharmacol, 16(4): 279-84. PMID: 8051988

 

Franco-Maside A, Caamaño J, Gómez MJ, Cacabelos R. 1994. Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer’s disease. Methods Find Exp Clin Pharmacol, 16(8): 597-607. PMID: 7760585 Clinical Trial.

 

Cacabelos R, Caamaño J, Gómez MJ, Fernández-Novoa L, Franco-Maside A, Vinagre D, Novo B, Zas R, Álvarez XA. 1995. Treatment of Alzheimer’s disease with CDP-choline: Effects on mental performance, brain electrical activity, cerebrovascular parameters, and cytokine production. Ann Psychiat, 5: 295-315.

 

Alvarez XA, Laredo M, Corzo D, Fernández-Novoa L, Mouzo R, Perea JE, Daniele D, Cacabelos R. 1997. Citicoline improves memory performance in elderly subjects. Methods Find Exp Clin Pharmacol, 19(3): 201-10. PMID: 9203170 Clinical Trial.

 

Alvarez XA, Mouzo R, Pichel V, Pérez P, Laredo M, Fernández-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano R, Cacabelos R. 1999. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol, 21(9):633-44. PMID: 10669911 Clinical Trial.

 

Álvarez XA, Sampedro C, Cacabelos R. 1999. Antiapoptotic effects of CDP-choline in a combined (Ab4/hypoperfusion) animal model of hippocampal neurodegeneration. Ann Psychiatry, 7:147-156.

0